1-4 of 4
Jennifer Grosjean
Close
Sort by
Journal Articles

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

Simone Boehrer, Lionel Adès, Thorsten Braun, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, Génèviève Le Roux, Claude Gardin, Antoine Martin, Stéphane de Botton, Pierre Fenaux, Guido Kroemer
Journal: Blood
Blood (2008) 111 (4): 2170–2180.
https://doi.org/10.1182/blood-2007-07-100362
Published: 2008
Includes: Supplemental data
Journal Articles

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Simone Boehrer, MD, Lionel Ades, MD, Thorsten Braun, MD, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, MD, Genevieve Le Roux, Claude Gardin, MD, Antoine Martin, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 399.
https://doi.org/10.1182/blood.V110.11.399.399
Published: 2007
Journal Articles

Flt3 Receptor Inhibition Abolishes Constitutive NFκB Activation in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Jennifer Grosjean, PhD, Lionel Ades, MD, Simone Bohrer, MD, PhD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2434.
https://doi.org/10.1182/blood.V110.11.2434.2434
Published: 2007
Journal Articles

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

Simone Boehrer, MD, Lionel Ades, MD, Lorenzo Galluzzi, Ken Olaussen, PhD, Thorsten Braun, MD, Jennifer Grosjean, PhD, Claire Fabre, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2438.
https://doi.org/10.1182/blood.V110.11.2438.2438
Published: 2007